RheumaTrace™

RheumaTrace™

RheumaTrace™ is a next-generation biomarker panel developed to advance precision medicine in rheumatology. Built on over 30 years of research and more than 200 publications, it features seven biomarkers that capture key aspects of connective tissue degradation and immune activity. RheumaTrace™ enables drug developers to track disease activity, predict treatment response, and identify target patient populations—supporting smarter, faster decisions in clinical development.

Order the RheumaTrace™ panel

The RheumaTrace™ biomarker panel

Introducing Nordic RheumaTrace™: a breakthrough biomarker panel for rheumatic diseases. Backed by three decades of research and over 200 peer-reviewed publications, this panel features seven carefully selected biomarkers.

These biomarkers delve into the complexities of connective tissue degradation and immune cell dynamics, providing invaluable insights for researchers and drug developers.

By pinpointing the disease pathway and determining the optimal dosage for positive outcomes, our panel is at the forefront of precision medicine in rheumatology.

Browse RheumaTrace™ panel

Biomarkers in the RheumaTrace panel™

The RheumaTrace™ biomarker panel for rheumatological diseases (RMDs) has been developed based on 3 decades of research and more than 200 peer-reviewed publications. The panel comprises seven distinct biomarkers, carefully selected to encompass the intricacies of connective tissue degradation and immune cell dynamics.

Together, these biomarkers offer researchers and drug developers invaluable insights into disease activity, the trajectory of disease progression, andthe efficacy of therapeutic interventions. By accurately identifying the critical pathway of the disease and the optimal dosage required to elicit a positive response, our panel represents a cutting-edge solution for precision medicine in rheumatology.

Benchmark doses & drugs with RheumaTrace™

The biomarkers in RheumaTrace™ are directly linked to the critical path of the disease and respond rapidly – within days and weeks – to effective drug intervention.

With a dose-dependent effect, the panel demonstrates that only efficacious doses of the drug reach clinically significant suppression, ultimately translating into a positive drug response.

As such, our panel has proven to be a valuable tool for dose-finding and efficacy prediction in phase I/II interventional trials, as well as insight into mode-of-mechanism in phase II/III.

The panel is likewise suitable for assessing and comparing drug response in head-to-head studies.

Figure 1. RheumaTrace™ shows pharmacodynamics and MoA

RheumaTrace™ is a smart translational medicine tool

As a smart translational medicine tool, RheumaTrace™ provides valuable support for drug (re)positioning efforts.

By including connective tissue destruction markers, which have been shown to be elevated in various inflammatory and autoimmune conditions, the panel enables targeted patient identification for drug trials and therapy.

Conversely, the absence of such markers in non-inflammatory conditions further enhances the panel’s specificity.

With the ability to accurately identify patient populations likely to respond to specific drugs, our panel represents a cutting-edge solution for personalized medicine in rheumatology.

Figure 2. RheumaTrace™ enables targeted patient identification

Elevate your research with RheumaTrace™ today!

Watch how the RheumaTrace™ biomarkers work

The science behind RheumaTrace™

  • The joint tissue is a complex structure composed of various connective tissues that collectively provide support for function, stability, and maintenance.

 

  • Nordic Bioscience’s biomarker technology enables direct measurement of these tissue fragments in blood, providing a precise and reliable assessment of tissue inflammation and disease activity in RMDs.

 

  • In rheumatological disorders (RMDs), homeostasis is disrupted by chronic inflammation, resulting in tissue destruction and the release of tissue fragments, particularly collagen fragments, into the bloodstream.

 

  • As these fragments are integral to the pathogenesis of RMDs and located on the critical path of any disease-modifying drug, our technology offers a valuable tool for guiding dose-finding and drug efficacy in drug development, and ultimately treatment decisions and monitoring patient outcomes.

Need further details?

RheumaTrace™ Supporting DocumentationDownload

Research questions answered by the RheumaTrace™ biomarkers

  • C1M is a biomarker for bone inflammation and connective tissue degradation. Measuring changes in C1M levels helps assess whether the compound reduces tissue damage commonly associated with rheumatic diseases.

  • C3M reflects the breakdown of type III collagen, a key component in soft tissues such as the synovium. Lower C3M levels after treatment suggest reduced inflammation and tissue destruction.

  • C4M measures the degradation of type IV collagen found in basement membranes of epithelial and endothelial tissues. This marker helps evaluate how the compound impacts tissue integrity in inflammatory conditions.

  • C2M is a marker of cartilage turnover. Changes in C2M levels can indicate whether the compound is slowing cartilage degradation and helping maintain joint space, essential for preserving mobility.

  • VICM reflects macrophage-driven inflammation through citrullinated vimentin breakdown. Monitoring VICM offers insights into how the compound modulates immune cell activation and chronic inflammation.

  • C4G is associated with granzyme B activity released by cytotoxic T-cells. Changes in C4G levels help determine whether the compound impacts T-cell involvement in inflammatory pathways.

  • CPa9-HNE is a marker of neutrophil elastase activity. This helps evaluate whether the compound dampens neutrophil-driven inflammation, which plays a role in acute and chronic tissue damage.

Get in touch

Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.
+45 4452 5252 Contact us via email!

    Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.

    Upcoming events

    No upcoming events

    News, events, and other resources

    Discover Nordic Bioscience